IV Flush Syringes Market

IV flush syringes are normal syringes used for clearing intravenous lines. Everyday millions of patients are required to clear their intravenous lines as this helps proper uninterrupted delivery of the medicine. The tubing needs to be cleaned as it can cause blood to mix with impurities. The IV Flush Syringes Market is valued at USD 498.7 Bn in 2026 and is projected to reach USD 753 Bn,  growing at a CAGR of 6% by 2033.

With significant rise in chronic diseases such as diabetes, cardiovascular diseases, rheumatic diseases, and cancer, the demand for IV flush syringes has received a tremendous impetus. There had been a record surge in total number of hospitalizations worldwide due to COVID-19, which has also created a high demand for IV flush syringes. Use of prefilled IV flush syringes will be the key highlight of the market during the forecast period.

The global flush syringes market will see significant capital investments in production lines and manufacturing. However, growing complications such as serious bacterial infection, air embolism, fluid overload, allergies, and rarely anaphylactic reactions has marred the market growth of IV flush syringes market. Moreover, rise in number of product recalls due to manufacturing and packaging defects has led to loss in confidence among the hospital suppliers and hospital procurement teams.

Prefilled IV Flush Syringes Poised to Drive Growth

Prefilled syringes has been reported less central line associated bloodstream infections as compared to normal IV flush syringes. According to Center for Diseases (CDC) it is now imperative to flush vascular access devices prior every infusion to assess catheter function thereby preventing serious catheter related complications. Prolong use or in-dwelling catheters, especially in peripheral venous catheters, may lead to complications such as cannulation, medications extravasation, occlusion, skin necrosis and phlebitis. To prevent such infection surgeons and nurses are increasingly using and instructing use prefilled IV flush syringes. The usage of IV flush syringes has led to significant decline in catheter failures. It has been studied that prefilled syringes took shorter flushing time as compared to manual ones.

Growing Investments and Expansion to Remain Primary Growth Undercurrent in IV Flush Syringes Market

Companies are increasingly expanding their manufacturing sites and using automation to speed up the ever-increasing demand. For instance, Medefil Inc. in the U.S. are in their advanced stage of setting up a new state-of-the-art manufacturing facility (200,000 sq. ft.) at Illinois. This expansion plan will help to add capabilities to manufacture injectable products in plastic and glass syringes, plastic and glass vials, and premix bags. In 2020, BD announced investment of US$1.2 Bn in prefilled syringes manufacturing capacities for next four years. This new manufacturing is expected to be operational by 2023. The investment will also fund capacity expansion, new product innovations, manufacturing technology enhancements and business continuity improvements across its existing network, all designed to maximize supply and reduce risks for pharmaceutical companies that rely on ready-to-fill syringes for their injectable drugs including complex biologics, vaccines, and small molecule.

In 2021, Baxter announced US$100 Mn expansion of its sterile manufacturing facility. Baxter operates this facility in collaboration with BioPharma Solutions. BPS to meet the growing demand for this delivery platform in both Europe and the United States. Prefilled syringes can enhance efficiency and easy-to-use for clinicians and have potential to minimize microbial contamination and reduce medication dosing errors during medication preparation, which are key considerations for patient safety.

Product Recalls to Hamper Supply and Reliability for Manufacturers in IV Flush Syringes Market

Reliability on suppliers for timely and good quality products has negatively affected the market growth with hospital management being put through taxing situation during such times. The reasons of recalls may be trivial at times such as packaging related errors or some important recalls such as bacterial contamination of sealed products has led to loss of confidence on healthcare hospital buyers. For instance, in August 2021, Cardinal Health initiated a nationwide recall of approximately 267 million MonojectTM Flush prefilled saline syringes as the products reported to reintroduce air into syringes after the air was expelled. This caused a potential threat of air embolism, which can consequently lead to serious issues.

North American Market to Thrive with High Adoption of Newer Products

Huge patient population, rise in total hospital admissions, and adoption of newer products for IV flush syringes has boosted the market growth in this region. Europe accounted to be the second largest market after North America. Rise in surgical procedures and established leaders in this region will drive the market growth. While, Asian region is expected to have the highest growth rate. Rising disposable income and rise in total number of surgeries is poised drive the North America IV flush syringes market.

Global IV Flush Syringes Market: Competitive Landscape

The key players operating in the global IV flush syringes market are 

• Becton, Dickinson and Company (BD)
•  Terumo Corporation
•  Nipro Corporation
•  Smiths Medical (part of ICU Medical)
• Fresenius Kabi
• Braun Melsungen AG
•  Medtronic plc
•  Cardinal Health
•  Teleflex Incorporated
•  Pfizer Inc.
•  Hospira (now part of Pfizer)
• STERIS plc
•  Patterson Medical
•  Halyard Health (now part of Owens & Minor)
•  Henke‑Sass, Wolf GmbH

Global IV Flush Syringes Market is Segmented as Below:

By Types

•  Saline IV Flush Syringe
•  Heparin IV Flush Syringe

By Applications

•  Hospital
•  Clinic
•  Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa